TS-005782 — This new IP introduces a modular, cell‑derived lipid nanoparticle (LNP) delivery platform engineered for highly efficient, biocompatible, and customizable delivery of nucleic acids and therapeutic agents, which is a significant improvement over existing synthetic LNP technologies.

TS-005781 — This invention introduces an advanced mRNA‑based gene‑therapy platform designed to treat both genetic and acquired elastin‑deficiency conditions, including autosomal dominant cutis laxa (ADCL), supravalvular aortic stenosis (SVAS), emphysema, aneurysms, and age‑related tissue degeneration. This IP represents a significant advancement over both plasmid‑based and existing mRNA therapies, establishing a safer, more effective strategy to address the root cause of elastin‑related diseases.

TS-005767 — This deep learning system, created to address a critical gap in child abuse evaluations, is built to estimate the time‑since‑injury healing fractures in infants and young children using radiographic imaging. The technology applies AI models to skeletal images of long‑bone fractures to generate more precise and objective estimates of fracture age than current subjective methods.

TS-005736 — This new clinical process and AI-enabled product is a comprehensive AI‑enabled platform designed to transform sleep healthcare delivery by supporting personalized, patient‑centric sleep management in primary care and community settings.

TS-005702 — This invention is a companion suite of tools and devices designed to complement the existing personalized SLEEPaide platform. The system combines AI‑powered clinical diagnostics (SLEEPehr) with an inclusive, community‑co‑designed monitoring device (SLEEPmonitor) that provides transparent, non‑invasive sleep assessment and sleep‑apnea detection for entire households while prioritizing accessibility, equity, and trust.

TS-005701 — This new process is a multigenerational, community‑driven sleep promotion campaign aimed to improve sleep health through culturally responsive, co‑designed materials and engagement strategies using a suite of products focused on addressing insufficient sleep and obstructive sleep apnea (OSA).

TS-005700 — This new device is a modular ergonomic attachment designed to connect to IV poles, wheelchairs, and hospital beds to reduce strain and overexertion among healthcare workers during patient transport by providing improved grip, leverage, and maneuverability through specialized features.

TS-005679 — This new IP is a secure digital pathology slide‑management platform that streamlines the entire whole‑slide imaging workflow by unifying specimen tracking, quality monitoring, and regulatory compliance into a single system. Unlike existing fragmented approaches that rely on spreadsheets, manual documentation, or limited LIS add‑ons, SlideFlow provides barcode‑based slot‑level tracking, automated timestamping, role‑based access control, and comprehensive audit logging to ensure data integrity and reduce human error.

TS-005675 — This IP is a comprehensive system designed to elevate sleep to a measurable and actionable vital sign within pediatric healthcare. Unlike consumer sleep technologies, this platform integrates directly into electronic health records and clinical workflows to reach all families, including perinatal, disabled, immigrant, and under‑resourced populations.

TS-005674 — This IP is a novel RNA‑targeted therapeutic strategy for alveolar rhabdomyosarcoma (ARMS) using CRISPR‑Cas13d to enable the highly specific degradation of the oncogenic mRNA while preserving the wild‑type PAX7 and FOXO1 genes, avoiding the genotoxicity risks associated with DNA‑targeting CRISPR systems.